TY - JOUR
T1 - Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest
AU - Ruijter, Barry J.
AU - Keijzer, Hanneke M.
AU - Tjepkema-Cloostermans, Marleen C.
AU - Blans, Michiel J.
AU - Beishuizen, Albertus
AU - Tromp, Selma C.
AU - Scholten, Erik
AU - Horn, Janneke
AU - van Rootselaar, Anne Fleur
AU - Admiraal, Marjolein M.
AU - van den Bergh, Walter M.
AU - Elting, Jan Willem J.
AU - Foudraine, Norbert A.
AU - Kornips, Francois H.M.
AU - van Kranen-Mastenbroek, Vivianne H.J.M.
AU - Rouhl, Rob P.W.
AU - Thomeer, Elsbeth C.
AU - Moudrous, Walid
AU - Nijhuis, Frouke A.P.
AU - Booij, Suzanne J.
AU - Hoedemaekers, Cornelia W.E.
AU - Doorduin, Jonne
AU - Taccone, Fabio S.
AU - van der Palen, Job
AU - van Putten, Michel J.A.M.
AU - Hofmeijer, Jeannette
AU - TELSTAR Investigators
N1 - Publisher Copyright:
Copyright © 2022 Massachusetts Medical Society.
Funding Information:
This trial was a pragmatic, multicenter clinical trial with randomized treatment assignments, open-label treatment, and blinded end-point evaluation at 11 intensive care units (ICUs) in the Netherlands and Belgium. Stepwise treatment to suppress rhythmic and periodic EEG patterns on continuously monitored EEG plus standard care was compared with standard care alone in comatose patients after cardiac arrest. The trial was supported by a grant from the Dutch Epilepsy Foundation (NEF14-18), which was not involved in trial design or conduct, data analysis, or manuscript preparation or review.
Publisher Copyright:
Copyright © 2022 Massachusetts Medical Society.
PY - 2022/2/24
Y1 - 2022/2/24
N2 - BACKGROUND Whether the treatment of rhythmic and periodic electroencephalographic (EEG) patterns in comatose survivors of cardiac arrest improves outcomes is uncertain. METHODS We conducted an open-label trial of suppressing rhythmic and periodic EEG patterns detected on continuous EEG monitoring in comatose survivors of cardiac arrest. Patients were randomly assigned in a 1:1 ratio to a stepwise strategy of antiseizure medications to suppress this activity for at least 48 consecutive hours plus standard care (antiseizure-treatment group) or to standard care alone (control group); standard care included targeted temperature management in both groups. The primary outcome was neurologic outcome according to the score on the Cerebral Performance Category (CPC) scale at 3 months, dichotomized as a good outcome (CPC score indicating no, mild, or moderate disability) or a poor outcome (CPC score indicating severe disability, coma, or death). Secondary outcomes were mortality, length of stay in the intensive care unit (ICU), and duration of mechanical ventilation. RESULTS We enrolled 172 patients, with 88 assigned to the antiseizure-treatment group and 84 to the control group. Rhythmic or periodic EEG activity was detected a median of 35 hours after cardiac arrest; 98 of 157 patients (62%) with available data had myoclonus. Complete suppression of rhythmic and periodic EEG activity for 48 consecutive hours occurred in 49 of 88 patients (56%) in the antiseizure-treatment group and in 2 of 83 patients (2%) in the control group. At 3 months, 79 of 88 patients (90%) in the antiseizure-treatment group and 77 of 84 patients (92%) in the control group had a poor outcome (difference, 2 percentage points; 95% confidence interval, -7 to 11; P=0.68). Mortality at 3 months was 80% in the antiseizure-treatment group and 82% in the control group. The mean length of stay in the ICU and mean duration of mechanical ventilation were slightly longer in the antiseizure-treatment group than in the control group. CONCLUSIONS In comatose survivors of cardiac arrest, the incidence of a poor neurologic outcome at 3 months did not differ significantly between a strategy of suppressing rhythmic and periodic EEG activity with the use of antiseizure medication for at least 48 hours plus standard care and standard care alone.
AB - BACKGROUND Whether the treatment of rhythmic and periodic electroencephalographic (EEG) patterns in comatose survivors of cardiac arrest improves outcomes is uncertain. METHODS We conducted an open-label trial of suppressing rhythmic and periodic EEG patterns detected on continuous EEG monitoring in comatose survivors of cardiac arrest. Patients were randomly assigned in a 1:1 ratio to a stepwise strategy of antiseizure medications to suppress this activity for at least 48 consecutive hours plus standard care (antiseizure-treatment group) or to standard care alone (control group); standard care included targeted temperature management in both groups. The primary outcome was neurologic outcome according to the score on the Cerebral Performance Category (CPC) scale at 3 months, dichotomized as a good outcome (CPC score indicating no, mild, or moderate disability) or a poor outcome (CPC score indicating severe disability, coma, or death). Secondary outcomes were mortality, length of stay in the intensive care unit (ICU), and duration of mechanical ventilation. RESULTS We enrolled 172 patients, with 88 assigned to the antiseizure-treatment group and 84 to the control group. Rhythmic or periodic EEG activity was detected a median of 35 hours after cardiac arrest; 98 of 157 patients (62%) with available data had myoclonus. Complete suppression of rhythmic and periodic EEG activity for 48 consecutive hours occurred in 49 of 88 patients (56%) in the antiseizure-treatment group and in 2 of 83 patients (2%) in the control group. At 3 months, 79 of 88 patients (90%) in the antiseizure-treatment group and 77 of 84 patients (92%) in the control group had a poor outcome (difference, 2 percentage points; 95% confidence interval, -7 to 11; P=0.68). Mortality at 3 months was 80% in the antiseizure-treatment group and 82% in the control group. The mean length of stay in the ICU and mean duration of mechanical ventilation were slightly longer in the antiseizure-treatment group than in the control group. CONCLUSIONS In comatose survivors of cardiac arrest, the incidence of a poor neurologic outcome at 3 months did not differ significantly between a strategy of suppressing rhythmic and periodic EEG activity with the use of antiseizure medication for at least 48 hours plus standard care and standard care alone.
KW - 22/1 OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85125216090&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2115998
DO - 10.1056/NEJMoa2115998
M3 - Article
C2 - 35196426
AN - SCOPUS:85125216090
SN - 0028-4793
VL - 386
SP - 724
EP - 734
JO - The New England journal of medicine
JF - The New England journal of medicine
IS - 8
ER -